Nationwide Experience With Off‐Label Use of Interleukin‐1 Targeting Treatment in Familial Mediterranean Fever Patients

• Published in: Arthritis care & research (2010) Vol. 70; no. 7; pp. 1090 - 1094
• Main Authors: Akar, Servet, Cetin, Pınar, Kalyoncu, Umut, Karadag, Omer, Sari, Ismail, Cınar, Muhammed, Yilmaz, Sedat, Onat, Ahmet Mesut, Kisacik, Bunyamin, Erden, Abdulsamet, Balkarli, Ayse, Kucuksahin, Orhan, Oner, Sibel Yilmaz, Senel, Soner, Tufan, Abdurrahman, Direskeneli, Haner, Oksuz, Ferhat, Pehlivan, Yavuz, Bayindir, Ozun, Keser, Gokhan, Aksu, Kenan, Omma, Ahmet, Kasifoglu, Timucin, Unal, Ali Ugur, Yildiz, Fatih, Balci, Mehmet Ali, Yavuz, Sule, Erten, Sukran, Ozgen, Metin, Sayarlıoglu, Mehmet, Dogru, Atalay, Yildirim, Gozde, Oner, Fatma Alibaz, Tezcan, Mehmet Engin, Pamuk, Omer Nuri, Onen, Fatos
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2018
• Subjects: Amyloidosis; Colchicine; Cytokines; Erythrocyte sedimentation rate; Excretion; Familial Mediterranean fever; Interleukin 1 receptor antagonist; Medical records; Patients; Proteinuria; Serum levels

Objective Approximately 30–45% of patients with familial Mediterranean fever (FMF) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine‐unresponsive or colchicine‐intolerant FMF patients are limited; the most promising alternatives seem to b...